key: cord-0762069-8q451b3n
authors: Prendecki, Maria; Clarke, Candice; Cairns, Tom; Cook, Terry; Roufosse, Candice; Thomas, David; Willicombe, Michelle; Pusey, Charles D.; McAdoo, Stephen P.
title: Anti-glomerular basement membrane disease during the COVID-19 pandemic
date: 2020-06-26
journal: Kidney Int
DOI: 10.1016/j.kint.2020.06.009
sha: 31417eb324d58f5cab9c3eba7667c9bbdfa2e7a2
doc_id: 762069
cord_uid: 8q451b3n

nan

Disclosures: None of the authors have any financial disclosures related to the submitted work.

Acknowledgements: The authors would like to thank Dr Eva Santos for assistance with HLA-typing.

Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune small vessel vasculitis. 1 The recent confirmation of spatial and temporal clustering of cases suggests that environmental factors, including infection, may trigger disease in susceptible individuals. 2 Since the identification of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), we have observed an unexpected number of new cases of anti-GBM disease presenting from our local population of approximately two million in north-west London, UK. Between December 2019 and April 2020, eight new cases were diagnosed, a five-fold increase above the background rate of 1.5 per million per year (Figure 1) . These cases were typical of anti-GBM disease in their clinical features, autoimmune serology, histopathology, HLA associations, and outcomes ( Table 1) .

Prior to their presentation with anti-GBM disease, all patients reported non-specific prodromal symptoms of 1-8 weeks duration. Five patients reported specific symptoms of respiratory tract infection and/or diarrheal illness during this period. At presentation with anti-GBM disease, five were tested for SARS-CoV-2 infection by viral RNA testing; none were positive. However, using serum samples stored at initial presentation, prior to immunosuppression and plasmapheresis, we detected circulating IgM and/or IgG to SARS-CoV-2 spike protein in four of eight patients, suggesting recent infection and a potential role in the onset of anti-GBM disease in some cases. The detection of IgM and IgG to SARS-CoV-2, with negative testing for viral RNA, is in keeping with the hypothesis that the viral infection initiates an aberrant adaptive immune response targeting basement membrane that becomes clinically apparent days to weeks after the acute infection

The first description of anti-GBM disease has been attributed to the American pathologist Ernest Goodpasture, who in 1919 (a century before the description of SARS-CoV-2) described a fatal pulmonary-renal syndrome that was considered secondary to an atypical influenza infection during the Spanish 'flu pandemic. 3 We do not know if his patient had anti-GBM disease, though there have since been descriptions of anti-GBM disease outbreaks during influenza epidemics. [4] [5] [6] [7] The cases of anti-GBM disease reported here are the first to occur in association with SARS-CoV-2 infection., and while a causal relationship remains speculative, we highlight a novel cluster of anti-GBM disease, and the potential for viral infections to trigger secondary autoimmunity, including rapidly-progressive forms of glomerulonephritis. 

Anti-Glomerular Basement Membrane Disease

Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease

The significance of certain pulmonary lesions in relation to the etiology of influenza

Goodpasture's syndrome associated with influenza A2 virus infection

A mini-epidemic of Goodpasture's syndrome clinical and immunological studies

Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4

Increased incidence of antiglomerular basement membrane antibody (anti-GBM) nephritis in the Mersey Region

ESKD 79 *Performed on Roche 6800 **Biomedomics lateral flow immunoassay. AKI, acute kidney injury; AKI-RRT, acute kidney injury requiring renal replacement therapy; ANCA, anti-neutrophil cytoplasm antibody; CKD, chronic kidney disease; CGN, crescentic glomerulonephritis; COPD, chronic obstructive pulmonary disease; ESKD, end-stage kidney disease; GBM, glomerular basement membrane; HD, heart disease; Ig, immunoglobulin; IP, in-patient; LRTI, lower respiratory tract infection; MPO, myeloperoxidase; OP, out-patient; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2;SLE, systemic lupus erythematosus; URTI, upper respiratory tract infection; UTI, urinary tract infection